Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S S Ellenberg

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
BMJ (Clinical Research Ed.)|January 12, 1991
Surrogate end points in clinical trialsS S Ellenberg
Controlled Clinical Trials|December 31, 1997
Informed consent: protection or obstacle? Some emerging issuesS S Ellenberg
Statistics in Medicine|August 28, 2001
Independent data monitoring committees: rationale, operations and controversiesS S Ellenberg
Oncology (Williston Park, N.Y.)|April 1, 1992
Do large, simple trials have a place in the evaluation of AIDS therapies?S S Ellenberg
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 26, 2001
Evaluating the safety of combination vaccinesS S Ellenberg
Controlled Clinical Trials|October 6, 2000
Fraud is bad, studying fraud is hardS S Ellenberg
Pharmacoepidemiology and Drug Safety|February 7, 2002
Surrogate endpoints: the debate goes onS S Ellenberg
The New England Journal of Medicine|May 24, 1984
Randomization designs in comparative clinical trialsS S Ellenberg
Statistics in Medicine|January 15, 1992
Randomized consent designs for clinical trials: an updateS S Ellenberg
Pharmacoepidemiology and Drug Safety|January 23, 2002
Safety considerations for new vaccine developmentS S Ellenberg
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
BMJ (Clinical Research Ed.)|January 12, 1991
Surrogate end points in clinical trialsS S Ellenberg
Controlled Clinical Trials|December 31, 1997
Informed consent: protection or obstacle? Some emerging issuesS S Ellenberg
Statistics in Medicine|August 28, 2001
Independent data monitoring committees: rationale, operations and controversiesS S Ellenberg
Oncology (Williston Park, N.Y.)|April 1, 1992
Do large, simple trials have a place in the evaluation of AIDS therapies?S S Ellenberg
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 26, 2001
Evaluating the safety of combination vaccinesS S Ellenberg
Controlled Clinical Trials|October 6, 2000
Fraud is bad, studying fraud is hardS S Ellenberg
Pharmacoepidemiology and Drug Safety|February 7, 2002
Surrogate endpoints: the debate goes onS S Ellenberg
The New England Journal of Medicine|May 24, 1984
Randomization designs in comparative clinical trialsS S Ellenberg
Statistics in Medicine|January 15, 1992
Randomized consent designs for clinical trials: an updateS S Ellenberg
Pharmacoepidemiology and Drug Safety|January 23, 2002
Safety considerations for new vaccine developmentS S Ellenberg
Pageof 6